Teratogenic effect of cisplatin in rats and the protective role of Sodium selenate (cas 13410-01-0)

Add time:07/26/2019    Source:sciencedirect.com

Eighty pregnant Sprague-Dawley rats were used in this study. They were allotted to four equal groups. The first group served as a control without any treatment while the other groups were given cisplatin, sodium selenate, and cisplatin + sodium selenate, respectively. Cisplatin was injected intraperitoneally in a dose of 5 mg/kgb wt. on the 12th day of gestation while sodium selenate was administered orally in a dose of 0.5 mg/kgb wt throughout gestation. Animals were sacrificed on the 20th day of gestation for fetal examination. Cisplatin produced significant elevation in the percentages of late resorption sites and dead foetuses compared with the control group. The mean foetal and placental weights were significantly reduced. Dwarf foetuses and subcutaneous (s/c) haemorrhage were also recorded in cisplatin-treated group. Visceral abnormalities were revealed in the form of dilated nares, anophthalmia and/or microphthalmia, dilated brain ventricles, hypertrophy of the heart, hypoplasia of the lung, hepatomegaly and dilated renal pelvis. Skeletal examination showed wide open fontanel, incomplete ossification of parietal and interparietal bones, incomplete ossification of sternum, reduction in the number or even complete absence of phalanges, sacral and/or caudal vertebrae. Histopathological examination of placentas in cisplatin-treated group revealed severe pathological alterations. Administration of sodium selenate significantly alleviated the afore-mentioned adverse effects of cisplatin on the fetuses and their placentas so we conclude that sodium selenate as an antioxidant has an effective protective role in cisplatin teratogenic effects.

We also recommend Trading Suppliers and Manufacturers of Sodium selenate (cas 13410-01-0). Pls Click Website Link as below: cas 13410-01-0 suppliers

Prev:Comparison of VITAMIN B12 (cas 13408-78-1), vitamin D and folic acid blood levels in patients with schizophrenia, drug addiction and controls
Next:Sodium selenate (cas 13410-01-0) activated Wnt/β-catenin signaling and repressed amyloid-β formation in a triple transgenic mouse model of Alzheimer's disease)